Economic Impact of Progressive Disease (pd) Following Frontline Therapy in Classical Hodgkin Lymphoma (Hl).

e19538 Background: Most patients (pts) with HL are cured with conventional chemotherapy (CT) +/-radiotherapy. For pts with PD, treatment options include conventional CT, autologous transplant, and allogeneic transplant. Few studies have defined the cost of therapy for PD. This study aimed to assess the economic burden of PD among pts with HL receiving 2nd and 3rd line therapy in a large network of community-based practices in the U.S.A. Methods: This retrospective, observational cohort analysis used the electronic health record (EHR) database maintained by McKesson Specialty Health/US Oncology Network to examine adult pts with classical HL who received CT (1st, 2nd, or 3rd line) between 1 Jan 2007 and 31 Dec 2011 and met all eligibility criteria. EHRs were supplemented with chart review and with data from the Claims Data Warehouse. Costs were derived from 2007 Medicare reimbursement rates and presented descriptively. Follow up time was censored at the last entry for disease status or 8 months after the da...